Archive For 7 January 2019

The GBC website is currently being improved

The GBC website is currently being improved

Some posts may be temporarily unavailable

GBC announces appointment of new COO

GBC announces appointment of new COO

  Geneva, Switzerland, October 2018. Following the recent successful financing of GBC-R1, a new molecule to treat allergic diseases (see also gbc-hpvac.com), and to support its other ongoing projects, the GBC is pleased to announce that Silvia Hansel has joined the GBC team as Chief of Operations.¬†Silvia will manage the day-to-day activities of the GBC,…

GBC-HpVac obtains seed financing

GBC-HpVac obtains seed financing

Geneva, Switzerland, October 2018. GBC-HpVac SA has successfully concluded a seed financing round, which enables it to proceed with the lead validation phase of its molecule GBC-R1. The production of new batches of GBC-R1 started in early October at a trusted GMP site and sufficient DS is now available to supply the upcoming bioequivalence, dose…

Go Top